UroToday- In the online version of European Urology, Dr. Curtis Nickel and associates report on the association of prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial, a 4-year, phase III placebo-controlled study that evaluates whether dutasteride (o.5mg) decreases the risk of biopsy detectable prostate cancer (CaP). They find evidence of a link between prostate inflammation and LUTS.

The REDUCE (Reduction by Dutasteride of prostate Cancer Events) enrolls men with a negative prostate biopsy and follows them for 4 years on either dutasteride or placebo. Participants were aged 50-75 years, with a PSA 2.5-10ng/ml (ages 50-60), 3-10ng/ml (age >60 years), and an IPSS